EC grants marketing authorization to Meda's Zyclara for treatment of actinic keratosis

Download PDF Copy

Aug 27 2012

NewsGuard 100/100 Score

Meda announced today that the European Commission (EC) has granted marketing authorization for Zyclara in the European Union. Zyclara (imiquimod 3.75% cream) is a patented product for the treatment of actinic keratosis. The approval is valid in all EU countries.

"Skin cancer is increasing and it is important to develop and improve the treatment of actinic keratosis. Zyclara is unique since it can treat large areas of the skin", said Anders Lönner, CEO of Meda AB.

Source:

MEDA

Posted in: Medical Condition News | Pharmaceutical News

Tags: Actinic Keratosis, Cancer, Carcinoma, Skin, Skin Cancer

Comments (0)

Download PDF Copy

Suggested Reading

Fine particulate matter linked to higher eczema risk

Fine particulate matter linked to higher eczema risk

Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease

Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease

Wearable ultrasound sensor revolutionizes continuous blood pressure monitoring

Wearable ultrasound sensor revolutionizes continuous blood pressure monitoring

Iron retention in skin linked to psoriasis: Could hepcidin be the missing piece in treatment?

Iron retention in skin linked to psoriasis: Could hepcidin be the missing piece in treatment?

Vitiligo linked to increased risk of heart disease and stroke, study finds

Vitiligo linked to increased risk of heart disease and stroke, study finds

Pomegranate peel extract restores skin balance, fights infections

Pomegranate peel extract restores skin balance, fights infections

Omega-3 fatty acids found to significantly reduce acne in new study

Omega-3 fatty acids found to significantly reduce acne in new study

Cranberry juice: A natural boost for women's skin health

Cranberry juice: A natural boost for women's skin health

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Study finds microplastics in semen and urine, linking PTFE exposure to lower sperm count